THE BRAXIA INSTITUTE
BRAXIA SCIENTIFIC INTRODUCES THE BRAXIA INSTITUTE Over 200 physicians and healthcare providers from Canada, U.S., and Asia to attend Braxia’s Symposium on rapid acting anti-depressants (RAAD) which include ketamine, esketamine and psychedelic therapies Braxia Institute aims to turn research into clinical action to achieve better outcomes for people with mental illness by closing the extraordinary gap between clinical practice and neuroscience research of ketamine and psychedelic treatment TORONTO, ONTARIO May 20, 2021 – Braxia Scientific Corp. (“Braxia Scientific” or the “Company”), (CSE: BRAX) (FWB: 496) (OTC: SHRMF), a research driven clinical platform developing and providing novel ketamine treatments for persons with depression and related disorders, is pleased to announce the launch of the Braxia Institute (“Braxia Institute”), the Company’s training Centre of Excellence focused on advancing psychiatric clinical practice and health services of ketamine and psychedelic treatment therapy for people with...